AB2009 authorizes persons who meet specified education, training, and supervision requirements to perform predonation total protein tests using digital refractometers inside licensed plasma collection centers. The bill ties permission to the department’s routine, fee‑supported inspection, requires five hours of device‑specific training certified by qualified clinical personnel, mandates onsite supervisory presence during testing, and sets device, quality control, and recordkeeping standards (including use of an FDA 510(k)‑approved BECS and three‑year retention of test records).
The change matters because it shifts some testing work away from traditionally licensed laboratory staff to trained center employees, creating operational flexibility for plasma centers while adding compliance duties: documentation, biannual competency checks, specific equipment controls, and confidentiality and contracting rules for departmental oversight. Compliance officers and clinical lab directors will need new policies and workflows to manage training, supervision, and data access under the department’s inspection authority.
At a Glance
What It Does
The bill permits specified non‑lab personnel to perform CLIA‑waived or moderate complexity total protein tests with a digital refractometer in licensed plasma collection centers if they meet education, training, and supervision conditions established by the department during its routine inspection. It also prescribes device criteria, quality control, electronic recording to an FDA 510(k)‑approved BECS, and three‑year record retention.
Who It Affects
Directly affects licensed plasma collection centers and their staff, CLIA lab directors and technical consultants, supervising physicians, registered nurses acting as supervisors, device manufacturers, and the California Department of Public Health (the department). Donor screening operations and FDA 510(k)‑listed BECS vendors will also be implicated.
Why It Matters
The bill formalizes delegation of a predonation screening test that intersects state inspection rules and federal CLIA requirements, creating a regulated path to expand non‑lab staffing for plasma screening while inserting new compliance obligations and inspection data flows that state regulators and centers must operationalize.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB2009 creates a narrow, regulated pathway for licensed plasma collection centers to let trained, non‑laboratory personnel run predonation total protein tests on-site using digital refractometers. Permission is conditional on the department’s finding—during its routine, fee‑supported inspection—that individuals meet education and documented training requirements, work under an approved supervisor who is physically present, and operate under center‑specific standardized procedures and job descriptions.
The bill cross‑references federal CLIA standards for education (high school diploma or equivalent) and for test complexity (waived or moderate complexity).
Training is tightly specified: the bill requires five hours of device‑specific instruction covering specimen acceptability, rejection criteria, and recording procedures. That training must be certified by a moderate complexity laboratory technical consultant, a California‑licensed physician, or the center’s licensed clinical laboratory director, and the center must keep proof of successful completion for departmental review.
Competency must be demonstrated by direct observation before testing on donors and reassessed every six months by the CLIA lab director or technical consultant; those competency records are confidential but must be produced to the department on request.Operational controls are also mandated. Refractometers must meet device and usage criteria (including being used within 30 feet of the donor and providing results without operator calculation), and centers must follow manufacturer‑specified control procedures consistent with 42 C.F.R. §493.1256.
Test results must be entered into an FDA 510(k)‑approved BECS, and refractometer test records must be retained for three years. The department may contract for collection and review of competency and performance information and that contract is explicitly exempted from certain state procurement rules; information obtained through that process is confidential and not a public record.
The Five Things You Need to Know
The bill requires five hours of device‑specific training, certified by a qualified consultant, physician, or clinical lab director, with documentation kept by the center.
Supervisors must be one of five authorized clinical roles (moderate complexity technical consultant, RN, physician, clinical lab director, or clinical lab scientist) and be physically onsite and available for consultation whenever tests are performed.
Each person’s competency must be observed and documented before donor testing and every six months thereafter by the CLIA lab director or technical consultant.
Test results must be recorded in an FDA 510(k)‑approved blood establishment computer system (BECS), and each refractometer system must follow manufacturer‑specified control procedures consistent with 42 C.F.R. §493.1256.
All digital refractometer test records must be retained for three years; the department may obtain competency and performance data, which the bill declares confidential and exempts from ordinary public records.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Department inspection ties permission to perform tests to conditions
Subdivision (a) conditions the authorization on the department’s routine, fee‑supported inspection and review of personnel reports and job descriptions. Practically, centers cannot self‑certify: the department must determine that individuals meet the educational and training bars laid out in the section before the center can use this delegation. That folds eligibility into the licensure inspection cycle and creates a compliance trigger for centers to prepare documentation ahead of inspection.
Minimum education, CLIA cross‑reference, and five‑hour device training
The bill adopts CLIA’s baseline for education (high school diploma or equivalent per CMS/CLIA) and adds a five‑hour module on performing total protein tests with a digital refractometer, covering specimen acceptability, rejection criteria, and recording. Crucially, the training must be certified by a named clinical authority (moderate complexity technical consultant, physician, or clinical lab director) and the center must keep proof of successful completion for department review — a documentation and certification workflow centers will need to build.
Who may supervise, onsite requirement, and required job descriptions and SOPs
Supervision may only be provided by one of five specified clinical roles and the supervisor must be physically onsite and available during testing. The supervising physician or clinical lab director must also provide written job descriptions for those performing tests and approve standardized procedures. The bill explicitly forbids the department from adding unrelated experiential requirements for supervisors when the center only performs plasma services, narrowing the scope of what regulators may demand for these centers versus blood banks.
Competency evaluation, control procedures, and BECS recording requirements
The statute requires direct‑observation competency evaluation by the CLIA lab director or technical consultant before donor testing and twice yearly afterwards, with written documentation retained for inspection. For each refractometer, centers must run control procedures at the frequency and number the manufacturer specifies and consistent with 42 C.F.R. §493.1256. Results must be entered into an FDA 510(k)‑approved BECS, which affects centers’ IT and validation responsibilities and ties operational compliance to specific vendor capabilities.
Device performance and use constraints for digital refractometers
Subdivision (b) lists technical and procedural constraints for eligible refractometers: proximity to donor (within 30 feet), capacity to deliver results without operator calculation, classification as waived or moderate complexity under CLIA, manual specimen handling steps (phlebotomy, centrifugation, pipetting), and minimal operator maintenance limited to basic cleaning and daily standardization. These device criteria limit which instruments qualify and frame how centers must document device selection and maintenance.
Confidential departmental review and three‑year record retention
Subdivision (c) lets the department require competency and performance information from centers and to contract for collection and review; it also declares these data confidential and exempts related contracts from certain public procurement rules. Subdivision (d) mandates three‑year retention of refractometer test records, making a discrete retention schedule that centers must integrate into record management and audit processes.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Licensed plasma collection centers — Gain staffing flexibility by delegating predonation total protein testing to trained non‑lab staff, potentially lowering labor costs and increasing throughputs if they can meet the training and supervision requirements.
- Supervising clinicians and CLIA lab directors — Obtain a clear, regulated delegation pathway that lets them expand operational capacity while controlling supervision, SOPs, and competency assessment within their purview.
- Donors and center operations — Potentially faster on‑site screening and reduced bottlenecks at donation intake when centers implement the delegated testing workflow with trained personnel.
Who Bears the Cost
- Licensed plasma collection centers — Must build and document training programs, maintain competency and personnel records, ensure BECS compatibility, run manufacturer‑specified controls, and host onsite supervisors, all of which create operational and compliance costs.
- Supervising clinicians and CLIA lab directors — Assume ongoing supervisory and direct‑observation responsibilities, increased oversight workload, and potential liability exposure tied to delegation and competency attestations.
- California Department of Public Health — Faces additional inspection evidence review and may need to contract for collection and review of competency data; though the bill allows procurement exemptions, administration and oversight still consume staff time and budget.
Key Issues
The Core Tension
The central tension is between operational flexibility and patient‑safety oversight: the bill aims to increase plasma center throughput and staffing options by letting trained non‑lab staff perform a screening test, but doing so risks diluting laboratory expertise and complicating regulatory oversight unless supervisors, training programs, device controls, and inspection practices are precisely defined and resourced.
The bill threads a narrow needle between delegation and laboratory oversight, but implementation will expose several frictions. First, it relies heavily on the department’s inspection judgment: centers must be “determined” compliant during routine inspections, which creates uncertainty about when delegation can begin and invites variability across inspectors unless the department issues clear implementation guidance.
Second, the statute defers many key definitions and performance expectations to external authorities (CLIA, manufacturer instructions, and referenced California regulations such as Title 17 §1036.2 and Section 1269), which means centers must manage a patchwork of federal and state rules and stay alert to any changes in those external standards.
The bill also carves out confidentiality for competency and performance data and exempts departmental contracts from parts of the Public Contract Code, raising transparency and procurement policy questions. Those exemptions speed data collection but reduce public oversight of how the department reviews delegated testing.
Finally, practical ambiguities remain — for example, what “used within 30 feet of the donor” means operationally in different floorplans, how the department will assess “sufficient proficiency” for supervisors, and how liability and malpractice insurance will respond when duties shift from licensed laboratory personnel to supervised non‑lab staff. Centers and supervisors will need to negotiate these gaps in policy and insurer interpretations.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.